1
|
Cottell E, Michalet D, Lispi M, Araujo TD, Gleixner R, Longobardi S, D'Hooghe T. Dose accuracy of the follitropin alfa pen injector 2.0, the follitropin alfa:lutropin alfa 2:1 combination pen injector 2.0 and the choriogonadotropin alfa pen injector 1.0 used for fertility treatment. Expert Opin Drug Deliv 2024; 21:337-346. [PMID: 38299472 DOI: 10.1080/17425247.2024.2311127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Accepted: 01/20/2024] [Indexed: 02/02/2024]
Abstract
BACKGROUND This study aimed to confirm that the incremental dose/clicks system dispenses accurate doses for the Merck family of fertility pen injectors. RESEARCH DESIGN AND METHODS Set doses (Vset) for three dose dial settings (minimum dose [Vmin], midpoint dose [Vmid] and maximum dose [Vmax] for the follitropin alfa, choriogonadotropin alfa [D2 classification: single use/variable dose], and follitropin alfa:lutropin-alfa 2:1 combination pen injectors) or a single Vset for the choriogonadotropin alfa (D1 classification: single use/single dose) were assessed. Last dose administered by the multi-dose device was assessed for the 900 IU, 450 IU, 300 IU and 150 IU follitropin alfa, and the 900:450 IU, 450:225 IU and 300:150 IU follitropin alfa:lutropin-alfa 2:1 combination pen presentations. RESULTS Dose accuracy tests for Vmin, Vmid and Vmax for the follitropin alfa and the follitropin alfa:lutropin-alfa 2:1 combination pen injectors, and last dose administered, were within acceptable limits according to ISO 11,608-1:2012/2014. Dose accuracy tests for the single use/single dose device classification and the single use/variable dose device classification of the choriogonadotropin alfa pen injector were also within the acceptable limits, according to ISO 11608-1:2000/2014. CONCLUSIONS The Merck family of fertility pen injectors functions reliably and the incremental dose/clicks system dispenses accurate doses.
Collapse
Affiliation(s)
| | - Damien Michalet
- Ares Trading S.A. Eysins (An affiliate of Merck KGaA), Switzerland
| | - Monica Lispi
- Merck Healthcare KGaA, Darmstadt, Germany
- School of Clinical and Experimental Medicine, Unit of Endocrinology, University of Modena and Reggio Emilia, Modena, MO, Italy
| | | | - Ralf Gleixner
- Ares Trading S.A. Eysins (An affiliate of Merck KGaA), Switzerland
| | - Salvatore Longobardi
- Global Clinical Development, Merck Serono S.p.A, Rome, Italy, an affiliate of Merck KGaA, Darmstadt, Germany
| | - Thomas D'Hooghe
- Merck Healthcare KGaA, Darmstadt, Germany
- Department of Development and Regeneration, Laboratory of Endometrium, Endometriosis & Reproductive Medicine, KU Leuven, Leuven, Belgium
- Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University Medical School, New Haven, CT, USA
| |
Collapse
|
2
|
Lispi M, Cottell E, Michalet D, Araujo T, Gleixner R, D'Hooghe T. P-598 Dose accuracy of the follitropin-alfa, follitropin-alfa/lutropin-alfa and choriogonadotropin-alfa pen injectors used for fertility treatment. Hum Reprod 2022. [DOI: 10.1093/humrep/deac107.550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
Do the Merck family of fertility pen injectors (follitropin-alfa, follitropin-alfa/lutropin-alfa, choriogonadotropin-alfa) meet the International Organization for Standardization (ISO 11608-1:2000/2012/2014) product-validation requirements?
Summary answer
Each presentation of the family of fertility pen injectors performed as per the state-of-the-art product-validation specifications for dose accuracy in ISO 11608-1:2000/2012/2014 under atmospheric conditions.
What is known already
Pen injectors for medically assisted reproduction must comply with ISO 11608-1:2000/2012/2014, which specifies essential performance requirements, including dose accuracy, and represent a benchmark for product reliability. Product-validation studies of the follitropin-alfa pen injector showed that three presentations (300 IU, 450 IU, and 900 IU) reliably dispensed accurate doses under a range of conditions, but no information was available for the follitropin-alfa/lutropin-alfa and choriogonadotropin-alfa pen injectors. This study was done to confirm that the incremental dose/clicks system was accurate for equivalence of volume (dose) delivered at standard atmospheric conditions for the complete Merck family of fertility pen injectors (follitropin-alfa, follitropin-alfa/lutropin-alfa, choriogonadotropin-alfa).
Study design, size, duration
Laboratory-based dose accuracy measurement testing was carried out under standard atmospheric conditions, as specified in ISO 11608-1:2000/2012/2014, between 2015 and 2020.
Participants/materials, setting, methods
Set doses (Vset) for three dose dial settings (minimum dose [Vmin], midpoint dose [Vmid] and maximum dose [Vmax] [follitropin-alfa, choriogonadotropin-alfa, and follitropin-alfa/lutropin-alfa]) or a single Vset (choriogonadotropin-alfa) were assessed, as appropriate. The last dose administered by the multi-dose device and cartridge and total extractable dose were assessed on the 900 IU and 300 IU follitropin-alfa and the 900 IU/450IU and 300/150 IU follitropin-alfa/lutropin-alfa-pen presentations. Sixty measurements per assessment were made for each Vset.
Main results and the role of chance
Measurements were performed at two manufacturing sites. Dose accuracy tests for Vmin, Vmid and Vmax (dose dial settings of 12.5 IU, 87.5 IU and 150 IU, respectively, for the 150 IU pen [n = 2,226 (one site)]; dose dial settings of 12.5 IU, 162.5 IU and 300 IU, respectively, for the 300 IU pen [n = 742 per site]; and dose dial settings of 12.5 IU, 237.5 IU and 450 IU, respectively, for the 450 IU [n = 180 per site] and 900 IU pens [n = 410 per site]) for the follitropin-alfa and the follitropin-alfa/lutropin-alfa pen injectors were within the acceptable limits defined in ISO 11608-1:2000/2012/2014. The results of further assessments of last dose and total extracted volume for each presentation of these devices were also within acceptable limits. Dose accuracy tests for the single use/single dose device classification (D1) of the choriogonadotropin-alfa pen injector (n = 210 [one site]) showed that the Vset (6,500 IU) was within the acceptable limits according to ISO 11608-1:2000/2012/2014. Furthermore, dose accuracy tests for the single use/variable dose device classification (D2) of the choriogonadotropin-alfa pen injector (n = 180 [one site]) showed that the Vmin (260 IU), Vmid (3,380 IU) and Vmax (6,500 IU) values were also the within acceptable limits.
Limitations, reasons for caution
These assessments were carried out by laboratory scientists, who are not the intended users of the pen injectors, and were not delivered into human tissue; therefore, although these conditions meet the international standards, they do not reflect the real-world use of the pen injectors by patients.
Wider implications of the findings
The Merck family of fertility pen injectors functions reliably and the incremental dose/clicks system dispenses accurate doses, providing users with confidence that they can accurately administer the prescribed dose and minimize drug wastage outside of a clinic environment, which is more important than ever in light of the COVID pandemic.
Trial registration number
not applicable
Collapse
Affiliation(s)
- M Lispi
- Merck Healthcare- Merck KGaA, Global Medical Affairs Fertility , Darmstadt, Germany
- University of Modena and Reggio Emilia, PhD School of Clinical and Experimental Medicine- Unit of Endocrinology , Modena MO, Italy
| | - E Cottell
- Merck Healthcare- Merck KGaA, Global Medical Affairs Fertility , Darmstadt, Germany
| | - D Michalet
- Ares Trading an affiliate of Merck Healthcare- Merck KGaA- Darmstadt- Germany, CHD Connected Health & Devices , Eysins, Switzerland
| | - T Araujo
- Ares Trading an affiliate of Merck Healthcare- Merck KGaA- Darmstadt- Germany, CHD Connected Health & Devices , Aubonne, Switzerland
| | - R Gleixner
- Ares Trading an affiliate of Merck Healthcare- Merck KGaA- Darmstadt- Germany, Global Healthcare Operations , Aubonne, Switzerland
| | - T D'Hooghe
- Merck Healthcare- Merck KGaA, Global Medical Affairs Fertility , Darmstadt, Germany
- KU Leuven, Department of Development and Regeneration , Leuven, Belgium
- Yale University, Department of Obstetrics and Gynecology, New Haven- CT , U.S.A
| |
Collapse
|
3
|
Agache P, Makki S, Blanc D, Constans S, Michalet D. Skin care in childhood. Curr Med Res Opin 1982; 7:15-22. [PMID: 7105804] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Childhood (3 to 9 years) is a calm period of constant growth throughout which social contacts are discovered and intelligence and discretion take place. Consequently, most diseases are infectious. Microrelief was found twice shallower and skin (epidermis + dermis) twice thinner than in adults. Intervals between furrows were reduced parallel to total body surface, thus ruling out the possible existence of special shelters favouring bacterial growth. Sweating is lower, as are skin surface lipid levels, in contrast to the post-natal period, inducing dryness of skin. Although total skin stiffness in vivo was found to be identical to young adult skin, skin chapping is much more frequent. Since detergents as well as extended hot baths may reduce the stratum corneum water binding capacity, they should be used with discretion. Hence, skin care in this period of age should be based upon different criteria than in adults.
Collapse
|